查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417246

嗜中性白血球低下症治疗市场报告：2030 年趋势、预测与竞争分析

Neutropenia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

嗜中性白血球低下症治疗的趋势与预测

全球嗜中性白血球低下症治疗市场的未来看起来充满希望，医院药房、零售药房和线上药房市场充满机会。预计到 2030 年，全球嗜中性白血球低下症治疗市场将达到约 203 亿美元，2024 年至 2030 年复合年增长率为 6.0%。这个市场的主要驱动力是癌症诊断的迅速增加，产业透过研发努力开拓嗜中性白血球低下症治疗方法，以及类风湿性关节炎、狼疮和克隆氏症等自体免疫疾病，以及感染疾病发生频率的增加，例如类风湿性关节炎、红斑性狼疮和克隆氏症。如败血症、结核病和肝炎。

嗜中性白血球低下症治疗市场洞察

Lucintel 预计集落刺激因子将在预测期内达到最高成长。

医院药房将继续成为该市场的最大部分。

预计亚太地区在预测期内将出现最高成长。

常问问题

Q.1嗜中性白血球低下症治疗药物的市场规模有多大？

A1. 到 2030 年，全球嗜中性白血球低下症治疗市场预计将达到 203 亿美元。

Q.2嗜中性白血球低下症治疗市场的成长预测是多少？

A2. 2024年至2030年，全球嗜中性白血球低下症治疗市场预计将以6.0%的复合年增长率成长。

Q.3 影响嗜中性白血球低下症治疗市场成长的关键因素有哪些：

A3. 该市场的主要驱动力是癌症诊断的快速增加、业界不断致力于透过研究和开发嗜中性白血球低下症治疗方法，以及类风湿性关节炎、狼疮和克隆氏症等自体免疫疾病，以及感染疾病。

Q4.市场的主要细分市场是：

A4.嗜中性白血球低下症治疗市场前景看好，医院药局、零售药局和网路药局市场都有机会。

Q5.市场的主要企业是：

A5. 主要的嗜中性白血球低下症治疗公司如下。

  • Teva Pharmaceutical Industries
  • Novartis
  • Mylan
  • Spectrum Pharmaceuticals
  • Beyondspring
  • Coherus Biosciences
  • Kyowa Kirin
  • Cellerant Therapeutics
  • Pfizer
  • Amgen

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计集落刺激因子在预测期内将出现最高成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 预计亚太地区在预测期内将出现最高成长。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章嗜中性白血球低下症治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球嗜中性白血球低下症治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按治疗分類的全球嗜中性白血球低下症治疗市场
    • 集落刺激因子
    • 抗生素
    • 抗真菌药物
    • 抗病毒药物
  • 按分销管道分類的全球嗜中性白血球低下症治疗市场
    • 医院药房
    • 零售药房
    • 网路药房

第四章 2018-2030年区域市场趋势及预测分析

  • 全球嗜中性白血球低下症症治疗市场（按地区）
  • 嗜中性白血球低下症治疗市场
  • 欧洲嗜中性白血球低下症症治疗市场
  • 亚太地区中性嗜中性白血球低下症治疗市场
  • 其他地区嗜中性白血球低下症治疗市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 全球嗜中性白血球低下症治疗市场按治疗的成长机会
    • 全球嗜中性白血球低下症治疗市场成长机会（按分销管道）
    • 全球嗜中性白血球低下症治疗市场按地区成长机会
  • 全球嗜中性白血球低下症治疗市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球嗜中性白血球低下症治疗市场的产能
    • 全球嗜中性白血球低下症治疗市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Teva Pharmaceutical Industries
  • Novartis
  • Mylan
  • Spectrum Pharmaceuticals
  • Beyondspring
  • Coherus Biosciences
  • Kyowa Kirin
  • Cellerant Therapeutics
  • Pfizer
  • Amgen
简介目录

Neutropenia Treatment Trends and Forecast

The ffuture of the global neutropenia treatment market looks promising with opportunities in the hospital pharmacies, retail pharmacies, and online pharmacies markets. The global neutropenia treatment market is expected to reach an estimated $20.30 billion by 2030 with a CAGR of 6.0% from 2024 to 2030. The major drivers for this market are surge in cancer diagnoses, growing industry commitment to pioneering neutropenia therapies through research and development, and increasing frequency of autoimmune illnesses including rheumatoid arthritis, lupus, and Crohn's disease, as well as infections like sepsis, TB, and hepatitis.

A more than 150-page report is developed to help in your business decisions.

Neutropenia Treatment by Segment

The study includes a forecast for the global neutropenia treatment by treatment, distribution channel, and region.

Neutropenia Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Colony-Stimulating Factor
  • Antibiotics
  • Antifungals
  • Antivirals

Neutropenia Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Onlne Pharmacies

Neutropenia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Neutropenia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies neutropenia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neutropenia treatment companies profiled in this report include-

  • Teva Pharmaceutical Industries
  • Novartis
  • Mylan
  • Spectrum Pharmaceuticals
  • Beyondspring
  • Coherus Biosciences
  • Kyowa Kirin
  • Cellerant Therapeutics
  • Pfizer
  • Amgen

Neutropenia Treatment Market Insights

Lucintel forecasts that colony-stimulating factor is expected to witness highest growth over the forecast period.

Within this market, hospital pharmacies will remain the largest segment.

APAC is expected to witness highest growth over the forecast period.

Features of the Global Neutropenia Treatment Market

Market Size Estimates: Neutropenia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Neutropenia treatment market size by treatment, distribution channel, and region in terms of value ($B).

Regional Analysis: Neutropenia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatment, distribution channel, and regions for the neutropenia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neutropenia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the neutropenia treatment market size?

Answer: The global neutropenia treatment market is expected to reach an estimated $20.30 billion by 2030.

Q.2 What is the growth forecast for neutropenia treatment market?

Answer: The global neutropenia treatment market is expected to grow with a CAGR of 6.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the neutropenia treatment market?

Answer: The major drivers for this market are surge in cancer diagnoses, growing industry commitment to pioneering neutropenia therapies through research and development, and increasing frequency of autoimmune illnesses including rheumatoid arthritis, lupus, and Crohn's disease, as well as infections like sepsis, TB, and hepatitis.

Q4. What are the major segments for neutropenia treatment market?

Answer: The future of the neutropenia treatment market looks promising with opportunities in the hospital pharmacies, retail pharmacies, and online pharmacies markets.

Q5. Who are the key neutropenia treatment market companies?

Answer: Some of the key neutropenia treatment companies are as follows.

  • Teva Pharmaceutical Industries
  • Novartis
  • Mylan
  • Spectrum Pharmaceuticals
  • Beyondspring
  • Coherus Biosciences
  • Kyowa Kirin
  • Cellerant Therapeutics
  • Pfizer
  • Amgen

Q6. Which neutropenia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that colony-stimulating factor is expected to witness highest growth over the forecast period.

Q7. In neutropenia treatment market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the neutropenia treatment market by treatment (colony-stimulating factor, antibiotics, antifungals, and antivirals), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Neutropenia Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Neutropenia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Neutropenia Treatment Market by Treatment
    • 3.3.1: Colony-Stimulating Factor
    • 3.3.2: Antibiotics
    • 3.3.3: Antifungals
    • 3.3.4: Antivirals
  • 3.4: Global Neutropenia Treatment Market by Distribution Channel
    • 3.4.1: Hospital Pharmacies
    • 3.4.2: Retail Pharmacies
    • 3.4.3: Onlne Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Neutropenia Treatment Market by Region
  • 4.2: North American Neutropenia Treatment Market
    • 4.2.2: North American Neutropenia Treatment Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Onlne Pharmacies
  • 4.3: European Neutropenia Treatment Market
    • 4.3.1: European Neutropenia Treatment Market by Treatment: Colony-Stimulating Factor, Antibiotics, Antifungals, and Antivirals
    • 4.3.2: European Neutropenia Treatment Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Onlne Pharmacies
  • 4.4: APAC Neutropenia Treatment Market
    • 4.4.1: APAC Neutropenia Treatment Market by Treatment: Colony-Stimulating Factor, Antibiotics, Antifungals, and Antivirals
    • 4.4.2: APAC Neutropenia Treatment Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Onlne Pharmacies
  • 4.5: ROW Neutropenia Treatment Market
    • 4.5.1: ROW Neutropenia Treatment Market by Treatment: Colony-Stimulating Factor, Antibiotics, Antifungals, and Antivirals
    • 4.5.2: ROW Neutropenia Treatment Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Onlne Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Neutropenia Treatment Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Neutropenia Treatment Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Neutropenia Treatment Market by Region
  • 6.2: Emerging Trends in the Global Neutropenia Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Neutropenia Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neutropenia Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Teva Pharmaceutical Industries
  • 7.2: Novartis
  • 7.3: Mylan
  • 7.4: Spectrum Pharmaceuticals
  • 7.5: Beyondspring
  • 7.6: Coherus Biosciences
  • 7.7: Kyowa Kirin
  • 7.8: Cellerant Therapeutics
  • 7.9: Pfizer
  • 7.10: Amgen